Format

Send to

Choose Destination
Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print]

Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.

Author information

1
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
2
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
3
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
4
Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea.

Abstract

Among prospectively enrolled adult patients with cancer receiving immune checkpoint inhibitors (ICIs, n=46) or cytotoxic agents (n=90), seroprotection and seroconversion rates after seasonal quadrivalent influenza vaccinations were higher with ICI than with cytotoxic chemotherapy. These results supports administration of annual influenza vaccinations for patients with cancer that receive ICIs.

KEYWORDS:

Influenza; immune checkpoint inhibitor; immune-related adverse event; immunogenicity; vaccination

PMID:
31680143
DOI:
10.1093/cid/ciz1092

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center